Adults with type 2 diabetes taking semaglutide had about 15% fewer bone fractures than adults taking other weight-loss medications, according to a retrospective analysis of health records from nearly 60,000 people, even though the semaglutide group lost more weight.
That last clause is what makes the finding notable. Substantial weight loss has generally been associated with bone loss, and concern that GLP-1 medications might weaken the skeleton has followed the drugs since they came into wide use.
The result was presented at ENDO 2026, the Endocrine Society's annual meeting, in June. It is an association drawn from observational data, not evidence that semaglutide prevents fractures, and the authors recommend that prospective studies be done to confirm the findings.
The Concern the Finding Runs Against
Weight loss reduces mechanical loading on the skeleton. Bone responds to the forces placed on it, and when body weight falls, the stimulus maintaining bone density falls with it.
Rapid weight loss using GLP-1 medications has been shown to produce thinner bones and fractures, while more moderate and slower loss appears to preserve bone mass better. These drugs produce rapid and substantial weight loss, which is why the question arose.
Loss of lean mass compounds it. GLP-1 therapy is associated with a reduction in lean body mass alongside fat, and muscle contributes to bone loading and to the balance and strength that prevent falls in the first place. Most fractures in older adults follow a fall rather than occurring spontaneously, so anything affecting stability matters as much as anything affecting bone density.
People with type 2 diabetes already have elevated hip fracture risk, and the presenting researcher noted several contributing factors including medications that cause hypoglycemia and raise fall risk, inflammation, and hyperglycemia itself.
Against that, some work has suggested semaglutide may promote bone health independent of weight. Sun H. Kim, an associate professor at Stanford University Medical Center, framed the result in those terms during her presentation, saying the findings highlight potential bone-protective effects of semaglutide and decouple the traditional clinical concern of weight-loss-induced skeletal decline.
The Study Design and What It Compared
Stanford investigators conducted a retrospective cohort analysis using the Atropos Health Eos electronic health record database, covering 2016 through 2023.
Participants were 59,879 adults 18 and older diagnosed with type 2 diabetes, with no history of prior fractures and no use of osteoporosis medications. Those exclusions matter, because both would independently affect fracture risk. The semaglutide group numbered 26,324 and the comparison group 33,555.
The comparison group is the design's defining feature. Semaglutide was compared not against no treatment but against other weight-loss therapies: dulaglutide, another GLP-1 receptor agonist, and the oral combinations phentermine-topiramate and bupropion-naltrexone.
Over a mean follow-up of 1,327 days, roughly three and a half years, the semaglutide group experienced 794 fractures against 1,045 in the comparison group. Fracture rates were 4.54% and 5.97%, a hazard ratio of 0.85, which is where the 15% figure comes from. Semaglutide was also associated with a larger decrease in body mass index.
"We found that semaglutide, compared to other weight loss medications, including another GLP-1 medication called dulaglutide, reduced risk of future fractures despite being associated with greater weight loss," Kim told Medical News Today.
The Limits That Keep This Preliminary
This is a conference presentation rather than a peer-reviewed publication, and abstract review is less rigorous than full journal review. The comprehensive research has not been published, so its complete limitations are not yet visible.
The comparator is the first thing to hold onto. Because semaglutide was measured against other active drugs rather than placebo, the finding speaks to relative risk among weight-loss options, not to whether semaglutide protects bone in absolute terms. Why one GLP-1 outperformed another on fractures remains an open question.
Confounding by indication is the second concern. Prescribers choose semaglutide for some patients and phentermine-topiramate for others, and those decisions reflect differences in insurance coverage, comorbidities, kidney function, cardiovascular history and overall health. Patients who receive semaglutide may differ systematically from the comparison group in ways that independently affect fracture risk.
Electronic health record data also captures what was recorded rather than what occurred. Fractures treated outside the contributing health systems would be missed, and that miss may not be evenly distributed between groups. Body mass index figures came from a smaller subset with available data.
The reported findings do not include bone mineral density measurements, fracture sites, or fall incidence, which would help distinguish a bone-strength effect from an effect on falling. Kim said a randomized trial would be the ideal next step, and that future work could examine whether tirzepatide shows a similar pattern. She reported no relevant financial disclosures.
Jairo Noreña, a former endocrinology fellow at Stanford, described the work as an important early step toward understanding the impact of semaglutide-induced weight loss on bone health, which is the appropriate weight to give it.
The Practical Reading for Patients
Nothing here changes prescribing guidance, and semaglutide is not a bone medication.
For patients already taking a GLP-1 medication for diabetes or weight management, this is modest reassurance against a specific worry rather than a reason to change anything. For patients weighing options, bone health is one consideration among many, and the evidence is not strong enough to drive the decision.
What does have established evidence for bone health during weight loss is unglamorous and applies regardless of medication: adequate protein intake, sufficient calcium and vitamin D, and resistance training, which places load on bone directly and preserves the muscle that supports it. The research team said it hopes the findings encourage bone-health monitoring in weight-loss programs, which is the more actionable implication.
People with additional fracture risk factors, including postmenopausal women, adults over 65, and anyone with a family history of osteoporosis or prior fragility fracture, have more reason to ask about bone density screening.
Nobody should start, stop or change a GLP-1 medication based on this finding. MedicalDaily has reported on what happens when people discontinue these drugs and on how many Americans now take them, both more immediate considerations for most patients than fracture risk.
Key Questions Answered
What did the study find? Among 59,879 adults with type 2 diabetes, those taking semaglutide had about 15% fewer fractures than those taking other weight-loss medications, despite greater weight loss. The semaglutide group had 794 fractures against 1,045 in the comparison group.
Does this prove semaglutide protects bone? No. This is a retrospective observational analysis showing an association. The authors explicitly recommended prospective studies to confirm the findings.
Why was bone loss a concern with these drugs in the first place? Weight loss reduces mechanical loading on the skeleton, and rapid weight loss with GLP-1 medications has been linked to thinner bones and fractures. GLP-1 therapy is also associated with loss of lean muscle mass, which supports both bone loading and balance.
What was semaglutide compared against? Dulaglutide, another GLP-1 receptor agonist, and the oral combinations phentermine-topiramate and bupropion-naltrexone. It was not compared against placebo, so the result describes relative risk among weight-loss options.
What are the main limitations? It is a conference abstract rather than a peer-reviewed paper. Prescribers choose between these drugs for reasons that also affect fracture risk, and electronic health record data can miss fractures treated elsewhere. Bone density, fracture sites and fall data were not reported.
Should anyone start or switch medications because of this? No. Nothing here changes prescribing guidance, and the evidence is not strong enough to drive a treatment decision.
What actually supports bone health during weight loss? Adequate protein, sufficient calcium and vitamin D, and resistance training, which loads bone directly and preserves supporting muscle. Anyone losing substantial weight should raise bone health with a clinician.
